Page 7 - Covid 26 July 2021

which act as tiny knives that pierce bacterial and viral membranes, thus killing them. “The ‘nanoknife’-modified fabrics demonstrated excellent antibacterial activity even after 60 cycles of washing,” said the lead researcher. All this makes it an excellent way to reuse masks and reduce biological waste generation.
Contact info:
j.amit@iitmandi.ac.in
Website link:
http://www.iitmandi.ac.in/news/articles/files/ Facemask_Apr2021.pdf
ICMR invites expression of interest for validation of rapid antigen
detection assays for COVID-19
ICMR invites applications for validation of rapid antigen detection tests for COVID-19 from all manufacturers who have developed rapid antigen test (RAT) kits. Requirements for validations are based on various categories, like first-time validation, revalidation, and validation with alternate sample types.
The gold standard RT-PCR diagnostic test for COVID-19 has limitations in terms of widespread availability. In view of this, there is urgent requirement for reliable and convenient rapid point- of-care antigen detection assays with high sensitivity and specificity. Such assays could be used as potential diagnostic tests in all possible public and private healthcare settings and made available for mass testing.
Deadline: Open till next announcement
Contact info:
guptanivedita.hq@icmr.gov.in, drneetu.vijay@icmr.gov.in
Website link:
https://www.icmr.gov.in/pdf/tender/Revised_EOI_for_Ag_kit_ validation_28062021.pdf
Serum Institute of India gets DCGI’s nod to manufacture Sputnik V
in India for test and analysis
The DCGI has granted permission to the Serum Institute of India (SII) to manufacture the Sputnik COVID-19 vaccine in India for examination, test and analysis with certain conditions, official sources said.
The Pune-based firm has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow in Russia to develop Sputnik V at its licensed Hadapsar facility.
According to the four conditions set by the DCGI, the Serum Institute will have to submit a copy of the agreement between SII and the Gamaleya Research Institute of Epidemiology and Microbiology for transfer of cell bank and virus stock and a copy of agreement for technology transfer with Gamaleya. The SII has to submit a copy of the RCGM permission to import cell bank and virus stock and a copy of the RCGM permission to initiate research and development of viral vector vaccine Sputnik V.
VOL. IV ISSUE 7
VIGYAN PRASAR 3
COVID-19 SCIENCE & TECHNOLOGY EFFORTS IN INDIA